Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K
Types of RNA01:20

Types of RNA

6.3K
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in regulating gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA Performs Diverse...
6.3K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

17.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.0K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

30
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
30
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

32
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
32

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lineage-restricted dependency on an oncofetal SNHG29-IGF2BP1 RNA axis in acute megakaryoblastic leukemia.

Leukemia·2026
Same author

Pharmacological clearance of senescent cells reduces inflammation, endothelial damage and cardiac fibrosis in HFpEF.

Cardiovascular research·2025
Same author

An interplay of non-coding RNAs regulates <i>CDH13</i> expression and affects endothelial function and coronary artery disease risk.

Research square·2025
Same author

Aging-regulated PNUTS maintains endothelial barrier function via SEMA3B suppression.

Communications biology·2024
Same author

DLC1 promotes mechanotransductive feedback for YAP via RhoGAP-mediated focal adhesion turnover.

Journal of cell science·2024
Same author

HDAC1/2 inhibitor therapy improves multiple organ systems in aged mice.

iScience·2024
Same journal

Correction: A Hidden Indicator of Cardiovascular Health: Serum Gamma-Glutamyl Transferase in Focus.

Journal of cardiovascular translational research·2026
Same journal

ChemoCardioNet: An Explainable Multimodal Transformer for Early Prediction of Chemotherapy-Induced Cardiotoxicity.

Journal of cardiovascular translational research·2026
Same journal

Metabolic Heterogeneity Across Heart Failure Subtypes Defined by Integrative Multi-Omics Analysis.

Journal of cardiovascular translational research·2026
Same journal

The Immediate Impact of Infarct Size on the Systemic Inflammatory Response: IL-6 as Central Mediator Identified through Biomarker and Proteomic Profiling.

Journal of cardiovascular translational research·2026
Same journal

Extracellular Vesicles Link Cerebral Ischemia to Coronary Microvascular Dysfunction - Role for RGD Motif-Activated Endothelin Signaling.

Journal of cardiovascular translational research·2026
Same journal

Tracing the pathogenic PLN p.(Arg14del) variant across the globe; more than just a local curiosity.

Journal of cardiovascular translational research·2026
See all related articles

Related Experiment Video

Updated: Sep 9, 2025

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
06:03

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model

Published on: June 11, 2020

9.2K

Long Non-coding RNA Based Therapy for Cardiovascular Disease.

Noelia Bellon Quinones1,2, Ruggero Belluomo3,4, Rio P Juni5,6

  • 1Institute for Cardiovascular Regeneration, Centre for Molecular Medicine, Goethe University, Frankfurt Am Main, Germany.

Journal of Cardiovascular Translational Research
|September 3, 2025
PubMed
Summary
This summary is machine-generated.

Long non-coding RNAs (lncRNAs) are key regulators in cardiovascular diseases (CVDs). Research highlights their potential as biomarkers and therapeutic targets, with advanced gene therapies showing promise for future treatments.

Keywords:
Cardiovascular diseasesGene therapyLong non-coding RNAs (lncRNAs)RNA therapeutics

More Related Videos

Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR
13:04

Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR

Published on: March 1, 2019

9.0K
Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification
10:39

Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification

Published on: November 28, 2016

11.4K

Related Experiment Videos

Last Updated: Sep 9, 2025

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
06:03

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model

Published on: June 11, 2020

9.2K
Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR
13:04

Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR

Published on: March 1, 2019

9.0K
Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification
10:39

Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification

Published on: November 28, 2016

11.4K

Area of Science:

  • Molecular Biology
  • Cardiovascular Research
  • Genetics

Background:

  • Cardiovascular diseases (CVDs) are a major global health concern, driving the need for novel therapeutic approaches.
  • Long non-coding RNAs (lncRNAs) are increasingly recognized as critical regulators of gene expression in cellular processes relevant to cardiovascular health and disease.

Purpose of the Study:

  • To review the functional roles of lncRNAs in the pathogenesis of cardiovascular diseases.
  • To explore the potential of lncRNAs as diagnostic biomarkers and therapeutic targets.
  • To discuss advancements in gene therapy and delivery strategies for lncRNA-based cardiovascular treatments.

Main Methods:

  • Literature review of studies on lncRNA function in cardiovascular disease.
  • Analysis of current RNA-targeting technologies (e.g., antisense oligonucleotides, siRNAs, CRISPR).
  • Evaluation of viral and non-viral delivery systems for lncRNA therapeutics.

Main Results:

  • lncRNAs are implicated in key CVD processes including hypertrophy, fibrosis, inflammation, and vascular remodeling.
  • Emerging RNA-targeting technologies offer potential therapeutic avenues for CVDs.
  • Challenges remain in the clinical translation of lncRNA-based therapies, particularly concerning delivery methods.

Conclusions:

  • lncRNAs represent a promising area for developing novel diagnostic and therapeutic strategies for cardiovascular diseases.
  • Further research into lncRNA biology and optimization of delivery systems are essential for clinical application.
  • lncRNA-based therapies hold the potential to significantly advance cardiovascular medicine.